161 related articles for article (PubMed ID: 25651421)
21. Fundamentals of immunology for understanding immunotherapy for lymphoma.
Ansell SM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):585-589. PubMed ID: 33275742
[TBL] [Abstract][Full Text] [Related]
22. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
23. Cellular composition of the tumor microenvironment.
Ansell SM; Vonderheide RH
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714465
[TBL] [Abstract][Full Text] [Related]
24. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
25. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
26. The role of T cells in the microenvironment of Hodgkin lymphoma.
Wein F; Küppers R
J Leukoc Biol; 2016 Jan; 99(1):45-50. PubMed ID: 26320264
[TBL] [Abstract][Full Text] [Related]
27. Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations.
Wogsland CE; Greenplate AR; Kolstad A; Myklebust JH; Irish JM; Huse K
Cytometry B Clin Cytom; 2017 Jan; 92(1):79-87. PubMed ID: 27933753
[TBL] [Abstract][Full Text] [Related]
28. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
29. Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms.
Davoodzadeh Gholami M; Kardar GA; Saeedi Y; Heydari S; Garssen J; Falak R
Cell Immunol; 2017 Dec; 322():1-14. PubMed ID: 29079339
[TBL] [Abstract][Full Text] [Related]
30. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.
Nam-Cha SH; Roncador G; Sanchez-Verde L; Montes-Moreno S; Acevedo A; Domínguez-Franjo P; Piris MA
Am J Surg Pathol; 2008 Aug; 32(8):1252-7. PubMed ID: 18594468
[TBL] [Abstract][Full Text] [Related]
31. Role of autologous CD4+ T cell clones in human B non-Hodgkin's lymphoma: aborted activation and G1 blockade induced by cell-cell contact.
Martin I; Bonnefoix T; Roucard C; Perron P; Lajmanovich A; Moine A; Leroux D; Sotto JJ; Garban F
Eur J Immunol; 1999 Oct; 29(10):3188-95. PubMed ID: 10540330
[TBL] [Abstract][Full Text] [Related]
32. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas.
Xerri L; Devilard E; Hassoun J; Olive D; Birg F
J Pathol; 1997 Oct; 183(2):182-7. PubMed ID: 9390031
[TBL] [Abstract][Full Text] [Related]
33. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia.
Tonino SH; van de Berg PJ; Yong SL; ten Berge IJ; Kersten MJ; van Lier RA; van Oers MH; Kater AP
Leuk Lymphoma; 2012 Sep; 53(9):1785-94. PubMed ID: 22397719
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells.
Lindner S; Dahlke K; Sontheimer K; Hagn M; Kaltenmeier C; Barth TF; Beyer T; Reister F; Fabricius D; Lotfi R; Lunov O; Nienhaus GU; Simmet T; Kreienberg R; Möller P; Schrezenmeier H; Jahrsdörfer B
Cancer Res; 2013 Apr; 73(8):2468-79. PubMed ID: 23384943
[TBL] [Abstract][Full Text] [Related]
35. S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.
Grum-Schwensen B; Klingelhöfer J; Beck M; Bonefeld CM; Hamerlik P; Guldberg P; Grigorian M; Lukanidin E; Ambartsumian N
BMC Cancer; 2015 Feb; 15():44. PubMed ID: 25884510
[TBL] [Abstract][Full Text] [Related]
36. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.
Chaperot L; Jacob MC; Molens JP; Manches O; Bensa JC; Plumas J
Leuk Lymphoma; 2000 Jul; 38(3-4):247-63. PubMed ID: 10830732
[TBL] [Abstract][Full Text] [Related]
37. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
[TBL] [Abstract][Full Text] [Related]
38. Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
Gergely L; Aleksza M; Váróczy L; Ponyi A; Sipka S; Illés A; Szegedi G
Eur J Haematol; 2004 May; 72(5):336-41. PubMed ID: 15059068
[TBL] [Abstract][Full Text] [Related]
39. Role of T- and B-lymphocytes in pulmonary host defences.
Moore BB; Moore TA; Toews GB
Eur Respir J; 2001 Nov; 18(5):846-56. PubMed ID: 11757636
[TBL] [Abstract][Full Text] [Related]
40. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
